Unique and Validated Drug Delivery Technology

The flexibility and the competitive advantage of our proprietary technology allow us to focus our development activities in complex extended-release delivery systems.

Our Technology

A Pipeline that Spans from NDAs to ANDAs

Our product portfolio includes both new products and controlled-release generic products, and cover therapeutic areas that range from neurology, cardiovascular, gastrointestinal tract, diabetes and pain. We have developed several drug delivery systems and a pipeline of products (some of which have received FDA approval) and product candidates in various stages of development, including ANDAs filed with the FDA (and one ANDS filed with Health Canada) and one NDA filing.

  • Oxycodone hydrochloride ER

    One of our non-generic products under development is our Oxycodone hydrochloride ER (abuse deterrent oxycodone hydrochloride extended release tablets) product candidate, intended as an abuse and alcohol-deterrent controlled-release oral formulation of oxycodone hydrochloride for the relief of pain. Oxycodone hydrochloride ER is designed to discourage common methods of tampering associated with misuse and abuse of prescription opioid analgesics.

    View Oxycodone HydroChloride ER 

  • Regabatin™

    Regabatin™ is another non-generic controlled-release product under development. It is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia and more.

    View Regabatin